Related references
Note: Only part of the references are listed.In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor
Zhonghua Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20
Brian E. McGillick et al.
BIOCHEMISTRY (2010)
Development of Peptide and Small-Molecule HIV-1 Fusion Inhibitors that Target gp41
Lifeng Cai et al.
CHEMMEDCHEM (2010)
HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics
Chungen Pan et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2010)
I-TASSER: a unified platform for automated protein structure and function prediction
Ambrish Roy et al.
NATURE PROTOCOLS (2010)
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors
Chungen Pan et al.
AIDS (2009)
Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide-Sensitive and -Resistant HIV Type 1 Strains
Chungen Pan et al.
JOURNAL OF VIROLOGY (2009)
HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide
Neelanjana Ray et al.
JOURNAL OF VIROLOGY (2009)
Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains as Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors
Zhi Qi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Design, Synthesis, and Biological Evaluation of N-Carboxyphenylpyrrole Derivatives as Potent HIV Fusion Inhibitors Targeting gp41.
Kun Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Selection of T1249-resistant human immunodeficiency virus type 1 variants
Dirk Eggink et al.
JOURNAL OF VIROLOGY (2008)
Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition
Yuxian He et al.
JOURNAL OF VIROLOGY (2008)
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: Implications for designing novel anti-HIV fusion inhibitors
Yuxian He et al.
JOURNAL OF VIROLOGY (2008)
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
Yuxian He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Potent D-peptide inhibitors of HIV-1 entry
Brett D. Welch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue
Raghavan Chinnadurai et al.
JOURNAL OF VIROLOGY (2007)
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor
Yiqun Deng et al.
BIOCHEMISTRY (2007)
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors
Neelanjana Ray et al.
JOURNAL OF VIROLOGY (2007)
HIV gp41 C-terminal heptad repeat contains multifunctional domains - Relation to mechanisms of action of anti-HIV peptides
Shuwen Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen
JP Lalezari et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
SW Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
JJ Eron et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment
S Menzo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
SB Jiang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
The entry of entry inhibitors: A fusion of science and medicine
JP Moore et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34
M Armand-Ugón et al.
ANTIVIRAL RESEARCH (2003)
The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation
JJ Dwyer et al.
BIOCHEMISTRY (2003)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
